Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia

Area of Science:

• Public Health
• Addiction Medicine
• Infectious Disease Control

Background:

• The COVID-19 pandemic significantly disrupted client-facing health services globally.
• Supervised injecting facilities (SIFs) faced operational challenges due to physical distancing requirements, leading to closures in Europe and North America.

Discussion:

• Australian SIFs, the Medically Supervised Injecting Centre (MSIC) in Sydney and the Medically Supervised Injecting Room (MSIR) in Melbourne, remained operational.
• These services implemented comprehensive strategies to maintain safer injecting spaces, deliver health information, and facilitate access to ancillary support and drug treatment.
• Continued operation of SIFs, despite potential COVID-19 transmission risks, is argued to provide greater public and individual health benefits than closure.

Key Insights:

• Australian SIFs successfully adapted services during the pandemic, demonstrating resilience in harm reduction.
• Maintaining essential services like SIFs is crucial for vulnerable populations, particularly people who inject drugs.
• The 'essential health service' designation for SIFs underscores their critical role in public health.

Outlook:

• Further research is needed to evaluate the long-term impact of pandemic-related adaptations on SIF operations and client outcomes.
• Sharing best practices from Australian SIFs can inform the operational strategies of similar services globally.
• Policy frameworks supporting the designation and continued funding of SIFs as essential services are vital for sustained public health impact.